Vivani Medical VANI

Vivani Medical, Inc. is a clinical stage biopharmaceutical company developing miniature drug implant candidates for extended duration delivery using its proprietary NanoPortal technology. This technology enables reversible near constant rate delivery of medicines for chronic diseases initially focusing on GLP1 receptor agonists for obesity and type 2 diabetes treatment.

Vivani Medical, Inc. currently does not generate product revenue as it remains in clinical and preclinical development stages. The company plans to generate future revenue through the potential commercialization of its drug implant candidates either via partnerships with established pharmaceutical companies or by building its own sales and marketing infrastructure following regulatory approval.

Vivani Medical, Inc. operates through two primary operational segments: its core biopharmaceutical drug implant business and its neurostimulation business conducted through its subsidiary Cortigent, Inc.

• Biopharmaceutical Drug Implant: This segment focuses on developing and commercializing miniature subdermal drug implant candidates utilizing the NanoPortal technology for sustained delivery of therapeutic agents with current emphasis on GLP1 based implants for obesity, type 2 diabetes, and related metabolic conditions in humans and companion animals.

• Neurostimulation: Conducted through Cortigent, Inc. this segment develops and advances pioneering neurostimulation systems aimed at helping patients recover critical body functions building on technology inherited from Second Sight Medical Products prior to the formation of Cortigent as a wholly owned subsidiary.

Vivani Medical, Inc. positions itself as an innovator in the drug delivery space competing within the large and growing markets for GLP1 receptor agonist therapies used in obesity and type 2 diabetes treatment. According to company disclosures, semaglutide products generated over $34 billion in combined sales during 2025, highlighting the substantial market opportunity for innovative delivery solutions. While facing established pharmaceutical giants such as Eli Lilly, Novo Nordisk, AstraZeneca, and Sanofi that dominate current GLP1 drug sales Vivani differentiates itself through its proprietary NanoPortal technology which offers potential advantages in medication adherence and reduced gastrointestinal side effects compared to existing oral and injectable options. The company believes its implant based approach could access underserved patient populations struggling with daily treatment regimens.

Vivani Medical, Inc. intends to serve patients suffering from obesity, type 2 diabetes, and related metabolic conditions through its biopharmaceutical segment with potential delivery via healthcare providers such as physicians and hospitals. For its neurostimulation segment through Cortigent the company targets patients requiring neurological functional restoration. Additionally its veterinary program aims to serve pet owners seeking treatment options for obesity and diabetes in companion animals like cats and dogs.